ISSN: 1859 - 2872
Cost-effectiveness of orphan drugs in multiple myeloma treatment: A systematic review
Main Article Content
Keywords
Abstract
Objective: Multiple myeloma is a hematological cancer that causes plasma cell accumulation, eventually leading to an abnormal protein production, known as monoclonal immunoglobulin in the patient’s serum and urine. There are 10 drugs for multiple myeloma treatment in Food and Drug Administration (FDA)’s and the Ministry of Health (MOH)’s Orphan Drugs List. This research aimed to systematically review studies on the cost-effectiveness analysis (CEA) of 10 orphan drugs, provided policy makers with a premise for making appropriate decisions in multiple myeloma treatment’s selection. Subject and method: A comprehensive systematic review was undertaken through the databases such as Pubmed, SpringerLink and Cochrane Library. The results were presented by describing CEA findings, with a focus on features belonging to cost-effectiveness evaluation. Result: 8 out of 10 orphan drugs in multiple myeloma treatment were analyzed with 18 available full-text cost-effectiveness studies, until 9/2021. 14 studies illustrated orphan drugs were cost-effective. Conclusion: These drugs generally had higher costs in multiple myeloma treatment. They could lead to a huge financial burden in multiple myeloma treatment for not only patients but also society. It is necessary to offer suitable financial aids to help patient promptly access the optimal treatment.
Article Details
References
2. Garrison LP, Wang STHH (2013) The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan. Oncologist 18(1): 27-36.
3. Usmani SZ, Cavenagh JD, Belch AR et al (2016) Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. J Med Econ 19(3): 243-258.
4. Cao Y, Zhao L, Zhang Tet al (2021) Cost-effectiveness analysis of adding daratumumab to bortezomib, melphalan, and prednisone for untreated multiple myeloma. Front Pharmacol 12(224).
5. Patel KK, Giri S, Parker TL et al (2021) Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. J Clin Oncol 39(10): 1119-1128.
6. Möller J, Nicklasson LMA (2011) Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: Lenalidomide plus dexamethasone vs bortezomib. J Med Econ 14(6): 690-697.
7. Jakubowiak AJ, Campioni M, Benedict A, et al. (2016) Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ 19(11): 1061-1074.
8. Pelligra CG, Parikh K, Guo S et al (2017) Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States. Clin Ther 39(10): 1986–2005.
9. Prinja S, Kaur G, Malhotra P et al (2017) Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus 33(1): 31-40.
10. Aceituno S, Gozalbo I, Appierto M et al (2018) Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile. Medwave 18(3): 7220.
11. Carlson JJ, Guzauskas GF, Chapman RH et al (2018) Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the united states. J Manag Care Spec Pharm 24(1): 29-38.
12. Campioni M, Agirrezabal I, Hajek R et al (2020) Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. Eur J Heal Econ 21: 219-233.
13. Vukićević Đ, Rochau U, Savić A et al (2020) Long-term effectiveness and cost effectiveness of multiple myeloma treatment strategies for elderly transplant-ineligible patients in Serbia. Zdr Varst 59(2): 83-91.
14. Dolph M, Tremblay GLH (2021) Cost effectiveness of triplet selinexor-bortezomib-dexamethasone (xvd) in previously treated multiple myeloma (mm) based on results from the Phase III BOSTON Trial. Pharmacoeconomics.
15. Marchetti M, Gale RP BG (2021) Cost-effectiveness of post-autotransplant lenalidomide in persons with multiple myeloma. Mediterr J Hematol Infect Dis 13(1): 2021034.
16. Qerimi V, Nestorovska AK, Sterjev Z et al (2018) Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia. Clin Outcomes Res 10: 327-338.
17. Borg S, Nahi H, Hansson M et al (2016) Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta Oncol. 55(5): 554-560.
18. Lima AO, Gimeno-Ballester V, Tamayo R et al (2019) Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells. Bone Marrow Transpl 54: 1908–1919.
19. Blommestein HM, Franken MG, van Beurden-Tan CHY et al (2021) Cost-effectiveness of novel treatment sequences for transplant-ineligible patients with multiple myeloma. JAMA Netw Open 4(3): 213497.
Article Sidebar
